BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE AS PRIMARY INDUCTION THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA SIGNIFICANTLY DECREASES BONE RESORPTION WHILE SPARING BONE FORMATION AS COMPARED TO THALIDOMIDE-DEXAMETHASONE

被引：0
|
作者：
Tosi, P. [1 ]
Zamagni, E. [1 ]
Tacchetti, P. [1 ]
Perrone, G. [1 ]
Ceccolini, M. [1 ]
Brioli, A. [1 ]
Pallotti, M. [1 ]
Pantani, L. [1 ]
Petrucci, A. [1 ]
Baccarani, M. [1 ]
Cavo, M. [1 ]
机构：
[1] Seragnoli Inst Hematol & Med Oncol, Bologna, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0659
引用
收藏
页码：265 / 265
页数：1
相关论文
共 50 条
  • [21] Addition of bortezomib improves efficacy of thalidomide/dexamethasone in newly diagnosed patients with multiple myeloma
    不详
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (02): : 78 - 79
  • [22] Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
    Xu, Peipei
    Zhou, Rongfu
    Xu, Jingyan
    Ouyang, Jian
    Shao, Xiaoyan
    Chen, Bing
    [J]. TRANSLATIONAL CANCER RESEARCH, 2019, 8 (05) : 2099 - 2106
  • [23] Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma
    Shen, Yunfeng
    Zhou, Xin
    Wang, Zhi
    Yang, Guohua
    Jiang, Yuanqiang
    Sun, Chao
    Wang, Jing
    Tong, Yi
    Guo, Hongfeng
    [J]. LEUKEMIA RESEARCH, 2011, 35 (02) : 147 - 151
  • [24] Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
    Cavo, M.
    Pantani, L.
    Pezzi, A.
    Petrucci, M. T.
    Patriarca, F.
    Di Raimondo, F.
    Marzocchi, G.
    Galli, M.
    Montefusco, V.
    Zamagni, E.
    Gamberi, B.
    Tacchetti, P.
    Brioli, A.
    Palumbo, A.
    Sonneveld, P.
    [J]. LEUKEMIA, 2015, 29 (12) : 2429 - 2431
  • [25] Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
    M Cavo
    L Pantani
    A Pezzi
    M T Petrucci
    F Patriarca
    F Di Raimondo
    G Marzocchi
    M Galli
    V Montefusco
    E Zamagni
    B Gamberi
    P Tacchetti
    A Brioli
    A Palumbo
    P Sonneveld
    [J]. Leukemia, 2015, 29 : 2429 - 2431
  • [26] Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma
    Lee, Yoojin
    Kim, Kihyun
    Sohn, Sang Kyun
    Back, Dongwon
    Moon, Joon Ho
    Lee, Je-Jung
    Jo, Jae-Cheol
    Lee, Won-Sik
    Shin, Ho-Jin
    Kim, Sung-Hyun
    Lee, Ji Hyun
    Bae, Sung Hwa
    Kim, Min Kyoung
    Lee, Ho Sup
    Min, Chang-Ki
    [J]. BLOOD, 2018, 132
  • [27] Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency
    Tosi, Patrizia
    Zamagni, Elena
    Tacchetti, Paola
    Ceccolini, Michela
    Perrone, Giulia
    Brioli, Annamaria
    Pallotti, Maria Caterina
    Pantani, Lucia
    Petrucci, Alessandro
    Baccarani, Michele
    Cavo, Michele
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) : 1115 - 1121
  • [28] Thalidomide/Dexamethasone Induction Therapy in Newly Diagnosed Myeloma Patients with Renal Failure
    Tosi, P.
    Tacchetti, P.
    Zamagni, E.
    Tacchetti, P.
    Ceccolini, M.
    Perrone, G.
    Brioli, A.
    Pallotti, M. C.
    Petrucci, A.
    Baccarani, M.
    Cavo, M.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S30 - S30
  • [29] Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone
    Tosi, Patrizia
    Zamagni, Elena
    Cangini, Delia
    Tacchetti, Paola
    Di Raimondo, Francesco
    Catalano, Lucio
    D'Arco, Alfonso
    Ronconi, Sonia
    Cellini, Claudia
    Offidani, Massimo
    Perrone, Giulia
    Ceccolini, Michela
    Brioli, Annamaria
    Tura, Sante
    Baccarani, Michele
    Cavo, Michele
    [J]. BLOOD, 2006, 108 (12) : 3951 - 3952
  • [30] VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma
    Pineda-Roman, M.
    Zangari, M.
    van Rhee, F.
    Anaissie, E.
    Szymonifka, J.
    Hoering, A.
    Petty, N.
    Crowley, J.
    Shaughnessy, J.
    Epstein, J.
    Barlogie, B.
    [J]. LEUKEMIA, 2008, 22 (07) : 1419 - 1427
12345